Section Arrow
Quote
CELC.NASDAQ
- Celcuity
Quotes are at least 15-min delayed:2026/05/31 11:20 EDT
Regular Hours
Last
 132.88
+1.97 (+1.50%)
Day High 
134.97 
Prev. Close
130.91 
1-M High
151.02 
Volume 
1.42M 
Bid
128
Ask
134
Day Low
126.77 
Open
131.09 
1-M Low
116.5 
Market Cap 
6.38B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 135.58 
20-SMA 133.27 
50-SMA 123.07 
52-W High 151.02 
52-W Low 10.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.90/0.77
Enterprise Value
6.71B
Balance Sheet
Book Value Per Share
1.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1172-0.0468-28.54%-- 
REPLReplimune Group8.69+4.01+85.68%-- 
CDTCDT Equity Inc.1.04+0.0899+9.46%-- 
CMNDClearmind Medicine Inc.3.58+1.13+46.12%-- 
OTLKOutlook Therapeutics0.73-0.01-1.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer andmetastatic castration-resistant prostate cancer, are ongoing.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.